Welcome!

News Feed Item

Infectious Diseases Point of Care Diagnostics - Products, Players and Outlook to 2017

NEW YORK, Feb. 25, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Infectious Diseases Point of Care Diagnostics - Products, Players and Outlook to 2017
http://www.reportlinker.com/p01105874/Infectious-Diseases-Point-of-Care-Diagnostics---Products-Players-and-Outlook-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

With the variable impact of influenza testing and much product innovation, POC diagnostics for infectious diseases is a wide area of high-growth opportunities

The market for Point-of-Care (POC) diagnostic products used in infectious diseases is expected to exceed US$1.8 billion by 2017, with year-on-year double digit growth from 2013 onwards. But there is a twist...

One of the largest segments within POC infectious disease diagnostics is influenza testing (US$180 million in 2011) and the overall value of the sector is influenced by the demand for tests during the critical influenza season. For example, the market rose rapidly in 2009 as a result of increased demand brought about by the pandemic H1N1 virus, declined in 2010 when there was a weak influenza season and rose again in 2011 when rates of influenza were higher. The fragmented nature of the sector, along with variable factors such as the level of influenza testing, means any assessment of the market requires a detailed appreciation of the products and players driving growth.

Competitive landscape: plenty of room for expansion?
There are 80+ companies active in the POC infectious disease sector. Alere, with 2012 revenues of US$2.4 billion of which US$565 million were due to infectious disease tests, is clearly the market leader, providing tests across all major product sectors. Alere's success has been built, in part, due to an aggressive acquisition strategy. Could that route be taken by others?

Consolidation through mergers and acquisitions is likely to continue in the POC diagnostics market in the future, while some development-stage companies are likely to fail. In light of the current economic situation, there remain good opportunities for companies with cash or financing available to them to add to their POC operations, both through acquisitions and by licensing technologies from companies that cannot afford to commercialise them themselves.

Wide applications in different geographical settings
The market for POC infectious disease testing can be broadly divided into testing in the developed world, and testing in emerging and developing countries. In the developed world, POC testing is most frequently conducted in professional healthcare settings, where it facilitates faster diagnosis and treatment than lab-based testing. Demand in the developed world varies significantly, with the US a strong adopter of the technology and Japan also frequently using POC influenza testing products. However, testing in Europe continues to be conducted mainly in central labs and the POC market is underpenetrated, hence an area of good opportunity.

POC can also have a big impact in emerging markets. With access to central lab testing often being sparse or non-existent, particularly in remote areas, POC testing can determine diagnosis at the point of need and is playing a key role in reducing the prevalence of diseases such as HIV and Malaria.

Contents

EXECUTIVE SUMMARY 1

INTRODUCTION 2
The Role Of POC Testing in Infectious Disease Diagnostics and Surveillance 2
POC Infectious Disease Testing Products 3
Customers of POC Infectious Disease Tests 3
Regulatory and Reimbursement Environment 4
CLIA Waiver 4
CURRENT MARKET DYNAMICS 6
Fig 1: POC Diagnostics in Relation to the IVD Market, 2011 6
Fig 2: Percentage of POC Diagnostics Market by Product, 2011 7
Regional Perspective 7
Fig 3: Professional POC Diagnostics Market by Region, 2011 8
POC Infectious Disease Testing Market 8
Fig 4: POC Infectious Disease Testing Market, 2007-2011 (US$ million) 9
Fig:5: POC Infectious Disease Testing Market by Product Type, 2011 (%) 10
COMPETITIVE LANDSCAPE 11
Select POC Diagnostics Companies' Sales, 2007-2011 (US$ million) 11
POC Infectious Disease Competitors 11
Market Leaders for POC Infectious Disease Testing Products 12
Select Companies' Infectious Disease Testing Sales, 2008-2011 (US$ million) 12
Fig:6: POC Infectious Disease Testing Market Shares by Competitor, 2011 (%) 12
Merger and Acquisition Activity 12
Key POC Infectious Disease Testing Mergers and Acquisitions, 2008-2012 13
GROWTH DRIVERS, RESTRAINTS AND FUTURE OPPORTUNITIES 15
Clinical Utility and Accuracy 15
Expanded Access to Screening in the US 16
POC Diagnostics as a Disruptive Technology 16
Future Technology: Next-Generation POC Diagnostic Products 17
Detecting Hospital-Acquired Infections 17
Summary: Market Drivers, Restraints and Opportunities 18
MARKET OUTLOOK 19
Fig 7: POC Infectious Disease Testing Market, 2011-2017E (US$ million) 20
Fig 8: POC Infectious Disease Testing Market Growth Rates, 2008-2017E (US$ million) 20

PRODUCTS AND TECHNOLOGIES 21

POC RESPIRATORY DISEASE DIAGNOSTICS 21
POC Influenza Testing 21
Performance and Use of Rapid Influenza Tests in the US 21
CDC Recommendations 22
CDC: Influenza Prevalence and Test Accuracy 22
POC Influenza Testing Market 22
Future Prospects 23
CLIA-Waived Flu Detection Products 24
Alere's Influenza Tests 24
Alverix/Becton Dickinson's BD Veritor System 24
Quidel's Sofia Analyzer and Sofia Influenza A+B Fluorescent Immunoassays 25
Quidel's QuickVue Influenza Tests 25
SA Scientific's SAS FluAlert 25
Other POC Flu Detection Products 25
bioMérieux' bioNexia Influenza A+B Tests 26
IQuum's Liat Influenza A/B Assay and the Liat Analyzer 26
Jant Pharmacal's Accutest Flu Test 27
Medix Biochemica's Actim Influenza A&B 27
Meridian Bioscience's TRU FLU 27
Mizuho Medy's Quick Chaser Flu A,B 27
OraSure Technologies' OraSure QuickFlu Rapid Flu A+B Test 27
Princeton BioMeditech's BioSign Flu A+B 27
Response Biomedical's Influenza A+B Test 28
Sekisui Diagnostics' OSOM Influenza A & B Test 28
Products in Development 28
Alere's iNAT System 28
Chembio's DPP Influenza Tests 28
Cepheid's GeneXpert 29
Enigma Diagnostics 29
Enigma ML (Mini Laboratory) 30
Lucigen's Nucleic Acid-Based POC Test 31
Respiratory Syncytial Virus Testing 31
Alverix/BD's BD Veritor System 32
Quidel's Sofia RSV Fluorescent Immunoassay 32
Quidel's QuickVue RSV 10 33
Response Biomedical's RSV Test 33
BioFire Diagnostics' FilmArray System 33
FilmArray Respiratory Panel 34
Other Respiratory Tests 34
Ani Biotech's Biocard Chlamydia Pneumoniae IgM Test 34
GenBio's ImmunoFLOW Mycoplasma IgM Test 34
Trinity Biotech's Uni-Gold Tests 35
OTHER PRIMARY CARE POC TESTS 36
Group A Streptococcus Tests 36
Currently Available POC Tests 36
Quidel's Sofia Strep A Fluorescent Immunoassay 37
H pylori Tests 37
Currently Available H pylori Tests 38
Exalenz Bioscience's BreathID System 38
Otsuka America Pharmaceutical's BreathTek UBT 39
Mononucleosis Tests 39
Currently Available POC Tests 39
Rotavirus and Adenoviral Enteritis Tests 40
Ani Biotech's Biocard Tests 40
Meridian Bioscience ImmunoCard STAT! Rotavirus 40
Nicox/Rapid Pathogen Screening's AdenoPlus 40
Orion Diagnostica's Diarlex, Rotalex and Adenolex Tests 40
Other Products 41
Ani Biotech's Biocard Candida and Trichomonas Tests 41
Gryphus Diagnostics' BVBLUE 41
Medix Biochemica's Actim Noro 41
POC HIV TESTING 42
Fig 9: HIV Prevalence, 2001-2011 (millions) 42
Fig 10: HIV Prevalence by Region, 2011 43
Fig 11: Number of New HIV Infections, 2001-2011 (million) 43
Fig 12: New HIV Infections by Region, 2011 44
Efforts to Combat HIV 44
Screening in the US 44
The Role of POC Testing 45
Market Dynamics 46
Fig:13: Global POC HIV Testing Market Shares by Company, 2011 47
Fig:14: US POC HIV Testing Market Shares by Company, 2011 47
Rapid HIV Tests 48
Currently Available POC Tests 48
CLIA-Waived Tests 49
bioLytical Laboratories' INSTI Rapid HIV-1 Antibody Test 49
Chembio Diagnostics' Lateral Flow HIV Tests 49
Fig 15: Chembio: HIV Lateral Flow Test Sales, 2008-2011 (US$ thousands) 50
OraSure Technologies' OraQuick Rapid Test Platform 50
OraSure's POC HIV Testing Sales, 2010-2011 (US$ thousands) 50
Fig 16: OraSure's OraQuick HIV Revenue by Region, 2011 51
Trinity Biotech's POC HIV Tests 51
Non-CLIA-Waived Tests 52
Alere's SD, Determine and Clearview HIV Tests 52
bioMérieux's VIKIA HIV 1/2 HIV Test 52
Bio-Rad's Multispot HIV-1/HIV-2 Rapid Test 52
Calypte Biomedical's Aware HIV-1/2 Tests 52
Fig 17: Calypte Biomedical: Aware Rapid HIV Test Sales, 2009-2011 (US$ thousands) 53
Chembio's Dual Path Platform Technology Products 53
FirstVue HIV Tests 54
Hema Diagnostic Systems 55
IND Diagnostic's One-Step Anti-HIV (1+2) Tests 55
Lab21's Biotec Tests 55
MedMira's Reveal HIV Tests 55
Savyon Diagnostics' HIVSav 1/2/0 Rapid SeroTest 56
Unimed's FirstSign HIV Duo 57
Products in Development 57
Alere's NAT Analyzer 57
Calypte Biomedical's Aware II (The Ani Platform) 57
Cepheid's GeneXpert System and Xpert HIV Viral Load Test 57
Chembio's SURE CHECK HIV OTC 58
IQuum's Liat System 58
MedMira's Dual HIV Test 58
POC CD4 Testing 59
Alere's Pima Point-of-Care CD4 Analyser 59
In Development - Daktari Diagnostics' Daktari CD4 59
POC HEPATITIS TESTS 61
Hepatitis B 61
Hepatitis C 61
HCV Screening in the US 62
POC HCV Testing 63
POC and Rapid HCV Tests: Sensitivity & Specificity 63
Available POC Tests 64
Key Rapid Tests 65
Alfa Scientific Designs' Instant-View Tests 65
bioMérieux's VIKIA HBs Ag Test 65
FirstVue's Hepatitis Rapid Test Kits 66
OraSure Technologies' OraQuick HCV Rapid Antibody Test 66
OraSure's POC HCV Testing Sales, 2010-2011 (US$ thousands) 66
Fig 18: OraQuick HCV Revenue by Region, 2011 67
Runbio Biotech's One Step Tests 67
In Development 67
bioLytical Laboratories' INSTI Test 67
Chembio Diagnostics' DPP HCV Test 68
MedMira's Rapid Tests 68
COMBINATION POC TESTS 70
TB and HIV 70
MedMira's Multiplo Rapid Tests 70
Multiplo HIV/HCV 70
Multiplo HBV/HIV/HCV 71
Multiplo TP/HIV 71
Products in Development 71
Chembio Diagnostics' DPP Syphilis/HIV Combination Test 71
MedMira's Development Products 71
POC TUBERCULOSIS TESTING 72
Multidrug-Resistant TB 72
TB and HIV 73
POC TB Testing 73
Cepheid's Xpert MTB/RIF 74
Concessionary Pricing 75
Alere's Determine TB LAM Ag Test 75
Products In Development 76
Alere/TwistDx's Recombinase Polymerase Amplification Technology 76
Applied Nanodetectors and the London School of Hygiene & Tropical Medicine 76
Chembio's DPP Tuberculosis Test 76
Enigma Diagnostics' Enigma ML (Mini Laboratory) 77
POC SEXUALLY-TRANSMITTED INFECTION TESTING 78
STI Testing and the Role of POC Diagnostics 78
POC STI Diagnostic Products 79
Currently Available POC Tests 79
Ani Biotech's Biocard Candida and Trichomonas Tests 80
Focus Diagnostics' HerpeSelect Express HSV-2 80
Gryphus Diagnostics' BVBLUE 80
Hema Diagnostic Systems' Rapid 1-2-3 Hema Syphilis 80
MedMira's Reveal TP Rapid Syphilis Test 80
Quidel's QuickView Chlamydia Test 80
RunBio Biotech's Tests 81
Savyon Diagnostics' SavvyCheck 81
Sekisui Diagnostics' OSOM Tests 81
Trinity Biotech's Uni-Gold HSV-2 Rapid Test 81
Products In Development 81
Atlas Genetics' POC System 81
bioLytical Laboratories' INSTI Test 82
Chembio's DPP Syphilis Tests 82
GenBio's ImmunoFLOW Herpes Simplex Virus Test 83
Randox Laboratories' Lab-on-a-Chip 83
POC TROPICAL DISEASE TESTS 85
Common Tropical Diseases 85
Malaria 85
Dengue Fever 85
Leptospirosis 86
Visceral Leishmaniasis 86
Typhoid 86
POC Testing 87
Currently Available POC Tests 88
Alere's Standard Diagnostics Tests 88
SD BIOLINE HAT 88
Hema Diagnostic Systems' Malaria and Typhoid Tests 89
Lab21's Tropical Disease Tests 89
Quest Diagnostics' Focus Dengue Rapid Tests 89
Products in Development 90
Chembio's DPP Leptospirosis 90
Chembio's DPP Visceral Leishmaniasis 90
EMERGING TECHNOLOGIES 91
POC Hospital-Acquired Infection Testing 91
Available Products and Developments 93
New-Generation POC Diagnostic Platform Technologies 93
Alere's POC Molecular Diagnostics Technologies 93
Ionian Technologies' Nicking Enzyme Amplification Reaction Technology 94
TwistDx' Recombinase Polymerase Amplification Technology 94
Atlas Genetics' POC System 94
Atonomics' Atolyzer 95
Bio-AMD's MPR and DSR 96
BioFire Diagnostics' FilmArray System 97
FilmArray Blood Culture ID Panel 97
FilmArray GI Panel 97
Biosensia's RapiPlex 98
Cepheid's GeneXpert 98
pes diagnosesysteme' respons IQ 99
Enigma Diagnostics' Products 100
Enigma ML (Mini Laboratory) 100
ResonSense Technology 101
Fiomi Diagnostics (Trinity Biotech) Forecast Technology 102
Immunexpress' SeptiCyte Technology 102
IQuum's Liat System 103
Liat Assays 104
Lucigen's Nucleic Acid-Based POC Tests 104
MycroLab 105
OPKO Health's OPKO Diagnostics Platform 106
Philips' Minicare 106
Radisens Diagnostics' POC Platform 107
Randox Laboratories' Lab-on-a-Chip 107
ReLIA Diagnostic Systems' ReLIA System 108
Rheonix' EncompassMDx Platform 108
T2 Biosystems' T2Dx System 108
Infectious Diseases 109
Tyrian Diagnostics' DiagnostIQ 110

POC MANUFACTURERS 111

POC COMPANY DIRECTORY 111

SELECTED COMPANY PROFILES 115

Alere 115
Recent Key Events 116
POC Infectious Disease Tests 116
New Products 116
Standard Diagnostics' Tests 117
Research and Development 118
Infectious Diease Mergers & Acquisitions 118
Ionian Technologies 118
TwistDx 118
Standard Diagnostics 119
Mologic, Jinsung Meditech, Biolinker and Long Chain International Corp 119
ACON Laboratories' Rapid Diagnostics Assets 119
Matria Healthcare 119
BBI Holdings 119
Other Acquisitions 120
Contracts and Alliances 120
OraSure Technologies 120
Chembio 120
Trinity Biotech 121
Financial Performance 121
Alere - Operating Results, 2007-2011 (US$ million) 121
Fig 19: Percentage of Alere's Revenue by Segment, 2011 122
Fig 20: Percentage of Alere's Revenue by Region, 2011 122
Alere Professional Diagnostics: Operating Results, 2007-2011 (US$ million) 122
Alere Professional Diagnostics: Net Sales & Services Revenue, 2007-2011 (US$ million) 123
Fig 21: Alere Professional Diagnostics: Net Sales & Services Revenue by Product, 2011 123
Latest Results 123
Calypte Biomedical 124
Aware Rapid Test Product Line 124
Aware HIV-1/2 OMT (Oral fluid) 125
Aware HIV-1/2 Oral OTC 125
Products in Development - Aware II (The Ani Platform) 125
Current Alliances 125
Manufacturing Contracts 126
Financial Performance 126
Calypte Biomedical: Operating Results, 2007-2011 (US$ thousands) 126
Calypte Biomedical: Revenue by Product Line, 2009-2011 (US$ thousands) 127
Fig 22: Calypte Biomedical: Percentage of Revenue by Product Line, 2011 127
Latest Results 127
Chembio Diagnostics 128
Recent Key Events 129
Lateral Flow Rapid HIV Tests 129
Dual Path Platform Technology Products 130
DPP HIV 1/2 Assay 130
DPP HIV 1/2 Confirmatory Test 130
Other Tests 131
Research and Development 131
SURE CHECK HIV OTC 131
DPP Technology Products in Development 131
Current Alliances and Contracts 133
Battelle Memorial Institute 133
Oswaldo Cruz Foundation of Brazil 133
National Institutes of Health 134
Alere 134
Infectious Disease Research Institute 134
Bio-Rad Laboratories 134
Financial Performance 135
Chembio - Operating Results, 2007-2011 (US$ thousands) 135
Chembio - Revenue by Type, 2008-2011 (US$ thousand) 136
Chembio - Product Sales by Region, 2010-2011 (US$ thousand) 136
Fig 23: Percentage of Chembio's Revenue by Type, 2011 136
Fig 24: Percentage of Chembio's Product Sales by Region, 2011 137
Latest Results 137
MedMira 138
Recent Key Events 139
Rapid Tests 139
Multiplo HIV/HCV 139
Multiplo HBV/HIV/HCV 140
Multiplo TP/HIV 140
Reveal HIV Tests 140
Reveal TP Rapid Syphilis Test 141
Reveal/MedMira hp Test H pylori Test 141
R&D Activities 141
Dual HIV Test 142
Current Alliances 142
United States Army 142
Advance Aid 143
Triplex International Biosciences 143
VWR International 143
Vitest 143
Financial Performance 143
MedMira - Operating Results, 2008-2012 (C$ thousands) 144
MedMira - Revenue by Region, 2007-2012 (C$ thousands) 144
Fig 25: MedMira - Revenue by Region, 2012 145
Latest Results 145
Meridian Bioscience 146
TRU FLU and TRU RSV 146
ImmunoCard STAT! HpSA H pylori Test 146
ImmunoCard STAT! Rotavirus 146
ImmunoCard STAT! Strep A 146
ImmunoCard STAT! MONO 146
ImmunoCard STAT! hCG Combo Test 147
Financial Performance 147
Meridian Bioscience - Operating Results, 2008-2012 (US$ million) 147
Meridian Bioscience - Third-Party Sales by Segment, 2008-2012 (US$ million) 147
Meridian Bioscience - Operating Income by Segment, 2008-2012 (US$ million) 147
Fig 26: Meridian Bioscience - Revenue by Segment, 2012 148
Meridian Bioscience - European Diagnostics Sales by Country, 2006-2011 (US$ million) 148
Outlook 148
OraSure Technologies 149
Recent Key Events 149
OraQuick Rapid Test Platform 149
OraSure's OraQuick ADVANCE HIV Test 149
OraSure's OraQuick In-Home HIV Test 150
OraQuick HCV Rapid Antibody Test 150
OraSure QuickFlu Rapid Flu A+B Test 150
Products in Development 150
Current Alliances and Licensing Agreements 150
Princeton BioMeditech 150
Alere 151
Merck 151
Ortho-Clinical Diagnostics 151
Financial Performance 151
OraSure - Operating Results, 2007-2011 (US$ million) 152
Fig 27: OraSure - Revenue by Business Area, 2011 152
OraSure Infectious Disease Testing Sales, 2010-2011 (US$ thousands) 153
Fig 28: OraQuick HIV Revenue by Region, 2011 153
Fig 29: OraQuick HCV Revenue by Region, 2011 153
Latest Results and Outlook 154
Quest Diagnostics 155
Focus Diagnostics' POC Products 155
HerpeSelect Express HSV-2 155
Focus Dengue Rapid Tests 156
Financial Performance 156
Quest Diagnostics - Operating Results, 2007-2011 (US$ million) 157
Quest Diagnostics - Sales and Earnings by Category, 2007-2011 (US$ million) 157
Fig 30: Quest Diagnostics - Revenue by Division, 2011 157
Latest Results and Outlook 157
Quidel 159
Recent Key Events 159
Sofia Analyzer and the Sofia Influenza A+B Fluorescent Immunoassay 159
QuickVue Rapid Tests 160
QuickVue Influenza Tests 160
QuickVue Group A Strep Tests 160
QuickVue RSV Tests 160
QuickVue+ Infectious Mononucleosis 161
QuickVue H Pylori gII Test 161
Financial Performance 161
Quidel - Operating Results, 2007-2011 (US$ million) 161
Quidel - Revenue by Product Type, 2008-2011 (US$ million) 162
Fig 31: Quidel - Revenue by Product Type, 2011 162
Fig 32: Quidel - Infectious Disease Revenue, 2005-2011 (US$ million) 162
Quidel - Revenue by Region, 2005-2011 (US$ million) 163
Fig 33: Quidel - Revenue by Region, 2011 163
Latest Results and Outlook 163
Sekisui Diagnostics 164
Point of Care Tests 164
OSOM RSV/Adenovirus Rapid Test 164
OSOM Influenza A & B Test 164
OSOM H pylori 164
OSOM Ultra Strep A 164
OSOM Strep A 165
OSOM Mono 165
OSOM Trichomonas Rapid Test 165
OSOM BVBLUE Test 165
OSOM C difficile Toxin A/B Test 165
Thermo Fisher Scientific 166
Sure-Vue Tests 166
Remel's Xpect Tests 167
Trinity Biotech 168
POC HIV Tests 168
Uni-Gold Recombigen HIV 168
Other POC Tests 169
Uni-Gold Giardia Test 169
Uni-Gold HSV-2 Rapid 169
Uni-Gold Legionella Urinary Antigen PLUS 169
Fiomi Diagnostics 169
Alere Licence 170
Financial Performance 170
Trinity Biotech Operating Results, 2007-2011 (US$ million) 170
Trinity Biotech - Sales by Product Line, 2006-2011 (US$ million) 171
Fig 34: Trinity Biotech - Sales by Product Type, 2011 171
Latest Results and Outlook 171

APPENDICES 172

APPENDIX 1 - LIST OF ABBREVIATIONS 172
APPENDIX 2 - REPORT METHODOLOGY 173


To order this report:
In_Vitro_Diagnostic Industry:
Infectious Diseases Point of Care Diagnostics - Products, Players and Outlook to 2017

 

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Leading companies, from the Global Fortune 500 to the smallest companies, are adopting hybrid cloud as the path to business advantage. Hybrid cloud depends on cloud services and on-premises infrastructure working in unison. Successful implementations require new levels of data mobility, enabled by an automated and seamless flow across on-premises and cloud resources. In his general session at 21st Cloud Expo, Greg Tevis, an IBM Storage Software Technical Strategist and Customer Solution Architec...
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, discussed how from store operations and ...
Blockchain. A day doesn’t seem to go by without seeing articles and discussions about the technology. According to PwC executive Seamus Cushley, approximately $1.4B has been invested in blockchain just last year. In Gartner’s recent hype cycle for emerging technologies, blockchain is approaching the peak. It is considered by Gartner as one of the ‘Key platform-enabling technologies to track.’ While there is a lot of ‘hype vs reality’ discussions going on, there is no arguing that blockchain is b...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
"As we've gone out into the public cloud we've seen that over time we may have lost a few things - we've lost control, we've given up cost to a certain extent, and then security, flexibility," explained Steve Conner, VP of Sales at Cloudistics,in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, discussed the b...
The use of containers by developers -- and now increasingly IT operators -- has grown from infatuation to deep and abiding love. But as with any long-term affair, the honeymoon soon leads to needing to live well together ... and maybe even getting some relationship help along the way. And so it goes with container orchestration and automation solutions, which are rapidly emerging as the means to maintain the bliss between rapid container adoption and broad container use among multiple cloud host...
In his session at 21st Cloud Expo, Michael Burley, a Senior Business Development Executive in IT Services at NetApp, described how NetApp designed a three-year program of work to migrate 25PB of a major telco's enterprise data to a new STaaS platform, and then secured a long-term contract to manage and operate the platform. This significant program blended the best of NetApp’s solutions and services capabilities to enable this telco’s successful adoption of private cloud storage and launching ...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Imagine if you will, a retail floor so densely packed with sensors that they can pick up the movements of insects scurrying across a store aisle. Or a component of a piece of factory equipment so well-instrumented that its digital twin provides resolution down to the micrometer.
"Since we launched LinuxONE we learned a lot from our customers. More than anything what they responded to were some very unique security capabilities that we have," explained Mark Figley, Director of LinuxONE Offerings at IBM, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Is advanced scheduling in Kubernetes achievable?Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, answered these questions and demonstrated techniques for implementing advanced scheduling. For example, using spot instances and co...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
Sanjeev Sharma Joins June 5-7, 2018 @DevOpsSummit at @Cloud Expo New York Faculty. Sanjeev Sharma is an internationally known DevOps and Cloud Transformation thought leader, technology executive, and author. Sanjeev's industry experience includes tenures as CTO, Technical Sales leader, and Cloud Architect leader. As an IBM Distinguished Engineer, Sanjeev is recognized at the highest levels of IBM's core of technical leaders.
The need for greater agility and scalability necessitated the digital transformation in the form of following equation: monolithic to microservices to serverless architecture (FaaS). To keep up with the cut-throat competition, the organisations need to update their technology stack to make software development their differentiating factor. Thus microservices architecture emerged as a potential method to provide development teams with greater flexibility and other advantages, such as the abili...